Autoimmune/autoinflammatory syndrome induced by adjuvants: a focus on silicone

• Published in: Clinical rheumatology Vol. 41; no. 11; pp. 3275 - 3283
• Main Authors: Ribeiro, Priscila Dias Cardoso, Sato, Emilia Inoue
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.11.2022; Springer Nature B.V
• Subjects: Adjuvants; Autoimmune diseases; Breast; Environmental factors; Epidemiology; Immune system; Medicine; Medicine & Public Health; Remission; Review Article; Rheumatology; Silicones; Breast implant illness; ASIA; Silicone; Silicone breast implant
• ISSN: 0770-3198; 1434-9949
• DOI: 10.1007/s10067-022-06274-0

Autoimmune/autoinflammatory syndrome induced by adjuvants (ASIA) was first described in 2011 to cover disorders characterized by dysregulation of the immune system after exposure to an adjuvant. In the present review, the authors focus on silicone-induced ASIA. In the last two decades, there has been worldwide increase in the use of silicone breast implant (SBI) as an aesthetic procedure, raising concerns for possible effects on the immune system, especially in people who already have previous immune dysregulation. The authors did a critical review of the most important articles referring to silicone-induced ASIA, including most recent studies regarding physiopathologic mechanism. Despite large-scale epidemiological studies conducted to assess the association between SBI and autoimmune/rheumatic disorders, the results remain inconclusive, and the debate over the safety of SBIs remains heated. The explantation of silicone breast has been indicated for silicone-induced ASIA with improvement of unspecific symptoms in the majority of patients; however, the outcome seems different in patients with definitive autoimmune rheumatic disease (AIRD). There is no prospective study evaluating the risk of flares after SBI in patients who already have an AIRD. Therefore, based on the literature, we cannot contraindicate the procedure; however, we need to advertise about the risk of ASIA to the patients with AIRD. Long-term safety and implant-related outcomes should be discussed with these patients, considering each case individually, assessing genetic and environmental factors, and determining if the autoimmune disease is in remission or not, for shared decision among patient and the physician.